The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The approval follows results based on the phase 3 AMPLIFY trial, which showed that this fixed-duration combination significantly improved progression-free survival compared to standard chemotherapy
In a letter published in HemaSphere, Claudia Bellofiore, MD, of the University of Pavia in Italy, and colleagues highlighted the need to expand clinical trial eligibility criteria for patients with immunoglobulin light chain (AL) amyloidosis due to the “critical impact” it has on treatment and survival.
Charles Craddock, CBE, FRCP, FRCPath, professor of hematology-oncology at the University of Birmingham and consultant hematologist at University Hospitals Birmingham, shares ASH 2025 highlights in acute leukemia.
Invivoscribe has announced the launch of its newly developed test for leukemia diagnostics, the LeukoStrat® KMT2A + MRD Assay, specifically for patients with acute myeloid leukemia (AML) who have the KMT2A rearrangement.
The FDA has released a new draft guidance focused on using minimal residual disease (MRD) and complete response (CR) as primary endpoints in multiple myeloma trials.
To access the SOHO Career Center click the following link.
